Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial.

ABSTRACT:

Background

Recurrent glioblastoma (GBM) has dismal outcomes and limited treatment options. Mebendazole (MBZ) has activity in glioma both in-vivo and in-vitro, and is well tolerated in combination with lomustine (CCNU) and temozolomide (TMZ). In this study, we sought to determine whether the addition of MBZ to CCNU or TMZ would improve overall survival (OS) in recurrent GBM.

Methods

In this phase II randomized open-label trial, adult patients with ECOG PS 0-3, with recurrent GBM who were not eligible for re-radiation, were randomized 1:1 to the CCNU-MBZ and TMZ-MBZ arms. CCNU was administered at 110 mg/m² every 6 weeks with MBZ 800 mg thrice daily and TMZ was administered at 200 mg/m² once daily on days 1-5 of a 28 days cycle with MBZ 1600 

SUBMITTER: Patil VM 

PROVIDER: S-EPMC9156991 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature